Vivek Balasubramaniam, MD, Awarded NIH Funding with University of Kentucky

Vivek Balasubramaniam, MD, will serve as a Co-Investigator/Subaward Principal Investigator for a grant from the National Institutes of Health/National Heart, Lung, and Blood Institute (NIH-NHLBI) to the University of Kentucky entitled, “Specific Lysis for Large-Volume, High-Purity Endothelial Progenitor Cell Isolates.” This 4-year R01 award to Principal Investigator Bradley Berron, PhD (University of Kentucky), develops a new approach to isolating a rare type of cell capable of repairing heart damage, which promises to deliver cells with fewer contaminants, faster, and at a lower cost than is possible today. This technology is also expected to both accelerate and reduce the cost of research across a broad spectrum of biological and medical sciences. Dr. Balasubramaniam’s role in the subaward, worth over $700,000 in direct costs, will be to perform the Endothelial Progenitor Cell (EPC) functionality studies in the proposal.